The Separate and Combined Effects of Vivitrol and Opiate Abstinence Reinforcement in the Treatment of Opioid Dependence

PHASE2CompletedINTERVENTIONAL
Enrollment

84

Participants

Timeline

Start Date

May 31, 2012

Primary Completion Date

December 12, 2016

Study Completion Date

August 6, 2017

Conditions
Opioid Dependence
Interventions
DRUG

Vivitrol

Participants receiving this intervention will receive the FDA-approved dose, route, and schedule of administration of VIVITROL. The dose of VIVITROL of 380 mg will be delivered intramuscularly every 4 weeks.

BEHAVIORAL

Employment-based opiate abstinence reinforcement

This intervention will require participants to provide opiate-negative urine samples on Monday, Wednesday and Friday to maintain their maximum pay. If a participant provides an opiate-positive urine sample, or fails to provide a scheduled sample, their base pay will be reset from $8 per hour to $1 per hour. On each day after the reset that the participant provides a urine sample that meets the opiate abstinence criteria and attends the workplace for at least 5 minutes, their base pay will increase by $1 per hour until it reaches the maximum of $8 per hour.

OTHER

Usual Care Control

Participants receiving this intervention will be invited to attend the workplace and outpatient drug abuse counseling.

Trial Locations (1)

21224

Johns Hopkins Bayview Center for Learning and Health, Baltimore

All Listed Sponsors
collaborator

National Institute on Drug Abuse (NIDA)

NIH

lead

Johns Hopkins University

OTHER

NCT01556425 - The Separate and Combined Effects of Vivitrol and Opiate Abstinence Reinforcement in the Treatment of Opioid Dependence | Biotech Hunter | Biotech Hunter